Compare ARMOUR Residential REIT, Inc. (ARR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs GSK plc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.73 (market cap $2.07B), while GSK plc trades at $50.43 (market cap $102.60B). The key difference: GSK plc is far larger — about 49.6× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (17.28%). Which is the better fit depends on your goals.
| ARR | GSK | |
|---|---|---|
Market Cap | $2.07B | $102.60B |
Sector | Financials | Health |
52-Week High | $19.12 | $61.18 |
52-Week Low | $14.05 | $38.22 |
Dividend Yield | 17.28% | 3.57% |
Enterprise Value | — | $123.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.74, up 1.18% with neutral technical signals. The REIT shows strong profitability with 97.43% net income margin and attractive valuation at P/E of 3.78 and P/B of 0.91. Recent Q2 2026 earnings beat expectations at $0.72 per share versus $0.69 estimate. The company maintains consistent dividend payments with recent $0.24 distributions. Cash flow trends show operational stability despite significant investing activities.
ARR presents value opportunity with deep discount to book value and high dividend yield, though mixed earnings performance and heavy mortgage-backed securities exposure create volatility risk. Analyst consensus remains cautious with 60% hold rating, reflecting balanced outlook between attractive valuation and sector-specific headwinds.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
